Why COVID-19 causes lung embolism, blood clots, bleeding and more

A recent study led by academics at Ume University in Sweden verified previous findings that show that most post-covid individuals are at higher risk for deep vein thrombosis, pulmonary embolism and hemorrhage!

Studies have shown that, regardless of the initial signs or symptoms of infection, the risk of deep vein thrombosis (a blood clot in the legs), pulmonary embolism (blood clots in the lungs) increases up to three months. Bleeding up to six months, and up to two months after Covid-19 infection.

Due to the observational nature of this study, researchers cannot conclusively determine the cause and they note various limitations that may affect their results.

For example, VTE may not be diagnosed in COVID-19 patients, COVID-19 testing was limited, especially during the first pandemic wave, and vaccination data was scarce.

But the question is what causes them. Other studies may have the answer.

Another study found that the blood of some COVID-19 patients was thicker than normal. According to the authors of a brief investigation, this may explain the tendency of blood to clot in patients with new coronavirus disease.

Researchers at Emery University in Atlanta have discovered a link between hyperviscosity and Covid-19. This can happen for a variety of reasons, including increased levels of blood plasma components such as red and white blood cells, platelets or proteins, or red blood cells.

According to the authors of the study, published in The Lancet Journal, blood clots are becoming more common in COVID-19 patients. After noticing this trend in their patients, the team set out to find an explanation.

In the intensive care unit of Emory University, 15 critically ill COVID-19 patients participated in the study. All of the patients were given anticoagulants, but their blood plasma concentrations were 95 percent higher than normal, according to the researchers. There were four patients with a pulmonary embolism, a limited blood supply to one leg, and a clotted blood clot attached to a kidney support system. Researchers have also discovered a significant link between plasma viscosity and sequential organ failure assessment scores, which are used to determine how dangerously ill a patient is.

According to the researchers, patients had significantly higher levels of fibrinogen, a protein found in blood plasma. According to them, this confirms previous reports of high doses of the drug in COVID-19 patients.

According to the authors, further research is needed to determine which component of the blood of Kovid-19 patients may cause hyperviscosity.

A study published in The Lancet Journal of Respiratory Medicine found that blood clots formed in the lungs of African American patients in New Orleans. The results were based on the autopsy with the consent of the relatives of ten patients who died in COVID-19.

Senior author Dr Richard Vanderhead said: “We found that the small vessels and capillaries in the lungs were obstructed by blood clots and associated bleeding, which significantly contributed to the decomposition and death of these patients.

“We also found high levels of D-dimer – a fragment of protein involved in breaking down blood clots. What we haven’t seen is myocarditis, or inflammation of the heart muscle, which early reports suggest has significantly contributed to death from Covid-19. “

Robert Story, a professor at the University of Sheffield who was not part of the study, said: “It is now well-known that inflammation increases the risk of clotting in the body because the concentration of protein in the blood plasma is responsible for clotting. Increased formation in keeping with the level of inflammation.

“What has surprised many physicians is the dramatic nature of the inflammatory response to COVID-19 which leads to life-threatening complications and it seems that we are seeing an exaggerated coagulation reaction in some hospitalized patients.”

This means that low doses of anticlotin drugs may be insufficient to address the problem, according to Story, “partly because the dose is low and partly because the effects stop before the next injection.

“However, doctors need to balance the risk of hemorrhage with the risk of hemorrhage, especially in Covid-19 patients who develop multiple organ failure, including the liver (which produces clotted protein) or require invasive procedures.”

According to the story, sick people in the arteries that supply the heart muscle or the brain are more susceptible to deep vein thrombosis, such as blood clotting conditions.

“We need to develop personalized strategies to control the risk of coagulation in patients with COVID-19 or other conditions associated with excessive inflammation.”

Image Credit: Getty

You were reading: Why COVID-19 causes lung embolism, blood clots, hemorrhage and who is at higher risk

Leave a Reply

Your email address will not be published.